Cite
HARVARD Citation
Powderly, J. et al. (n.d.). Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3. Journal for immunotherapy of cancer. p. . [Online].